US · Healthcare · Biotechnology
EPS came in at -0.88 against a street estimate of -0.92 — a beat of 4.3%.
Analysts rate First Tracks Biotherapeutics a strong buy (12 buy, 0 hold, 0 sell out of 12) with an average price target of $74.17.
| Fund | Stake |
|---|---|
| EcoR1 Capital, LLC | 7.56% |
| TCG Crossover Management, LLC | 6.89% |
| FMR Inc | 4.89% |
| Affinity Asset Advisors, LLC | 4.84% |
| BlackRock Inc | 4.67% |
| Trails Edge Capital Partners, LP | 3.60% |
| State Street Corp | 3.60% |
| Vanguard Capital Management, LLC | 3.46% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • First Tracks Biotherapeutics is a clinical-stage biotechnology company developing antibody therapies for autoimmune and inflammato | 2026-11-03 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Third-quarter 2026 net loss was $31.4 million, or $0.88 per share, compared with a $41.9 million loss, or $1.50 per share, in thir | 2026-11-03 |
| Material agreement · Q4 2026 HEADLINE NUMBERS • First Tracks Biotherapeutics closed a private placement on October 19, 2026. • The company issued 6,106,870 shares of common stoc | 2026-10-20 |
| Material agreement · Q4 2026 HEADLINE NUMBERS • First Tracks Biotherapeutics agreed to sell 6,106,870 common shares at $32.75 per share in a private placement. • Expected gross | 2026-10-15 |
| Reg FD disclosure · Q4 2026 HEADLINE NUMBERS • First Tracks Biotherapeutics (Nasdaq: TRAX) announced positive topline data from the first Phase 1b cohort of ANB033 in celiac dis | 2026-10-13 |
| Quarterly report · Q2 2026 FIRST TRACKS BIOTHERAPEUTICS, INC. — 10-Q SUMMARY FOR Q2 2026 HEADLINE NUMBERS • Cash position: $168.0 million as of June 30, 2026 (down from $238.2 | 2026-08-12 |
| Results announced · Q3 2026 FIRST TRACKS BIOTHERAPEUTICS Q2 2026 SUMMARY HEADLINE NUMBERS • Cash and cash equivalents: $168.0 million as of June 30, 2026 • Net loss for six mon | 2026-08-12 |
| Material agreement · Q2 2026 FIRST TRACKS BIOTHERAPEUTICS, INC. – 8-K SUMMARY BUSINESS & SEGMENT HIGHLIGHTS • Company entered into a Sublease Agreement on June 15, 2026 with Ana | 2026-06-22 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for First Tracks Biotherapeutics — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.